A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release
NCT ID: NCT05287906
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
69 participants
INTERVENTIONAL
2022-04-15
2024-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
NCT05499702
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
NCT02033876
Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota
NCT02061124
Effects of GLP-1 Formula on GLP-1 and Glucose Regulation
NCT07082062
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal Weight Group
The normal weight group incudes men and women with BMI 18.5 - 24.9 kg/m2, and will receive all interventions.
Water
Each subject will receive one control and three treatments in the crossover design. The control contains water only.
Glucose
Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
Steviol Glycosides
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
Steviol Glycosides plus glucose
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
Rebaudioside A
A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
Overweight Group
The overweight group includes men and women with BMI 25.0 - 29.9 kg/m2, and will receive all interventions.
Water
Each subject will receive one control and three treatments in the crossover design. The control contains water only.
Glucose
Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
Steviol Glycosides
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
Steviol Glycosides plus glucose
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
Type 2 Diabetes Mellitis Group
The T2DM group includes men and women with BMI 25.0 - 34.9 kg/m2, HbA1c \<8%, and will receive all interventions.
Water
Each subject will receive one control and three treatments in the crossover design. The control contains water only.
Glucose
Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
Steviol Glycosides
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
Steviol Glycosides plus glucose
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Water
Each subject will receive one control and three treatments in the crossover design. The control contains water only.
Glucose
Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
Steviol Glycosides
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
Steviol Glycosides plus glucose
Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
Rebaudioside A
A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has BMI 18.5 to 24.9 kg/m2, inclusive, for the normal weight group.
3. Subject has BMI 25.0 to 29.9 kg/m2, inclusive, for the overweight group.
4. Subject has BMI 25.0 to 34.9 kg/m2, inclusive, and HbA1c \<8%, and is not taking any injectable hypoglycemic medication(s) or oral glucagon-like peptide 1 (GLP-1) mimetic(s), for individuals with T2DM.
5. Subject has consumed ≤670 mL (24 oz) of artificially sweetened or steviol glycoside sweetened soft drinks per week for at least 1 month before screening.
6. Consumption of less than 2 yogurts per week (that are sweetened with HIS).
7. Subject has a score of at least 7 on the Vein Access Scale.
8. Subject is willing to follow his/her regular physical activity pattern throughout the study period.
9. Subject is willing to refrain from consuming marijuana throughout the study period.
10. Subject is willing to refrain from consumption of alcoholic beverages for 48 h prior to each clinic visit.
11. Subject is willing to refrain from vigorous physical activity for 24 h prior to each clinic visit. According to the World Health Organization (WHO), vigorous physical activity may include running, fast cycling, fast swimming, or moving heavy objects.
12. Subject is willing to abstain from tobacco use 1 h prior to and during each clinic visit and has no plans to change smoking, vaping or other nicotine use habits during the study period
13. Subject understands the study procedures and is willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study Investigator.
Exclusion Criteria
2. Subject has atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease \[symptomatic (e.g., myocardial infarction, angina, transient ischemic attack or stroke of carotid origin) or \>50% stenosis on angiography or ultrasound\] or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
3. Subject has a history or presence of a clinically important medical condition that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
4. Individual has a positive urine drug screen for illicit drugs.
5. Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at visit 1 (week -1).
6. Subject has a history of cancer in the prior 5 years, except for non-melanoma skin cancer or carcinoma in situ of the cervix.
7. Subject has history of moderate or severe renal failure, moderate or severe liver disease, gall bladder removal, pancreatic disease, or a gastrointestinal disorder that might influence the digestion or absorption of nutrients or impact colonic function as judged by the Investigator.
8. Subject has history of major trauma or a major medical or surgical event requiring hospitalization within 3 months of visit 1 (week -1).
9. Subject has used antibiotics within 4 weeks of visit 1 (week -1) or has a condition likely to require the use of antibiotics during the study.
10. Subject has an active infection or has used antibiotics within 7 d of any test visit. Those with an active infection and/or using antibiotics must wait at least 7 d after the infection resolves or antibiotic use is complete. The test period will be extended for completion in these cases.
11. Subject has experienced a change in body weight of ±4.5 kg (\~10 pounds) over the 3 months prior to visit 1 (week -1).
12. Subject has unstable use (initiation or dose alteration) of any antihypertensive medication within 4 weeks prior to visit 1 (week -1).
13. Subject has unstable use (initiation or dose alteration) of any of the following lipid-altering medications within 4 weeks prior to visit 1 (week -1): statins, ezetimibe, bempedoic acid, bile acid sequestrants, fibrates, niacin (drug form), and/or omega-3 fatty acid drugs.
14. Subject has unstable use (initiation or dose alteration) of a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor within 3 months of visit 1 (week -1).
15. Subject has used weight-loss drugs (including over-the-counter medications and/or supplements) within 4 weeks of visit 1 (week -1).
16. Subject has used or has a condition likely to require the use of systemic corticosteroid drugs within 4 weeks of visit 1 (week -1).
17. Subject has unstable use (initiation or dose alteration) of medications known to influence carbohydrate metabolism, including, but not limited to, adrenergic receptor blockers, thiazide diuretics, hypoglycemic medications, and/or antipsychotics within 4 weeks prior to visit 1 (week -1).
18. Subject has used cannabidiol (CBD) products within two weeks prior to visit 2 (week 0) and throughout the study.
19. Subject has a known allergy, sensitivity, or intolerance to any ingredients in the study beverages.
20. Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
21. Subject has extreme dietary habits (e.g., vegan or very low carbohydrate diet).
22. Subject has a current or recent history (past 12 months), or strong potential, for drug or alcohol abuse. Alcohol abuse is defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).
23. Subject has a history of a diagnosed eating disorder (e.g., anorexia nervosa or bulimia nervosa).
24. Subject has been exposed to any non-registered drug product within 30 d of visit 1 (week -1).
25. Subject has a condition the Investigator believes would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cargill
INDUSTRY
Midwest Center for Metabolic and Cardiovascular Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin Maki, PhD
Role: STUDY_DIRECTOR
MB Clinical Research & Consulting, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Excellence Medical and Research
Miami Gardens, Florida, United States
Advanced Research for Health Improvement
Naples, Florida, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MB-2110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.